TRIPLE 1500 (1500 mg R1626 bid +
peginterferon alfa-
2a + ribavirin; n = 31); or standard of care (SOC) (
peginterferon alfa-
2a + ribavirin; n = 20). At 4 weeks HCV RNA was undetectable (<15 IU/mL) in 29%, 69%, and 74% of patients in the DUAL 1500, DUAL 3000, and TRIPLE 1500 arms, respectively, compared with 5% of patients receiving SOC, with respective mean reductions in HCV RNA from baseline to week 4 of 3.6, 4.5, 5.2, and 2.4 log(10) IU/mL.